Comparative Pharmacology
Head-to-head clinical analysis: GASTROVIST versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROVIST versus RENOVIST II.
GASTROVIST vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrovist (diatrizoate meglumine) is a iodinated radiographic contrast agent that attenuates X-rays, enhancing visualization of the gastrointestinal tract. It acts as a hyperosmolar agent, drawing fluid into the bowel lumen and providing positive contrast for imaging.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Oral: 50-100 mL of a 30% w/v solution (300 mg iodine/mL) administered orally 30-60 minutes before imaging. Repeat dose if necessary for adequate visualization. Rectal: 100-200 mL of a 30% w/v solution as enema for CT colonography.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (glomerular filtration): >95% of iodinated contrast is excreted unchanged in urine within 24 hours; <5% fecal or biliary.
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent